Infants with SMA type 1 treated with nusinersen can maintain the same level of breathing or respiration over two years, according to a new study. Typically, infants with SMA type 1 — the most severe form of the condition — experience a rapid decline in their breathing abilities as the condition progresses. The median survival for infants with SMA type 1 is 8 to 13.5 months. Respiratory failure is the most common cause of death.
Sold as Spinraza, nusinersen is the first disease-modifying therapy for SMA. It was approved by the U.S. Food and Drug Administration (FDA) in 2016.
For the study — conducted by Dr. Moran Lavie and their colleagues at Tel Aviv University in Israel — 20 infants with SMA type 1 were assessed both before and after two years of nusinersen treatment. Among the participants, 16 infants were already on assisted ventilation at the start of the study; the other four were not.
Share your thoughts with others. Click here to add a comment. |
During the two years, the researchers observed several outcomes. These included:
“Our experience was that most patients were stable in their need for assisted ventilation and did not worsen as expected given the natural history of the disease, nor did they improve as one would hope,” the authors of the study wrote.
They noted that further studies are necessary to see whether starting treatment with nusinersen earlier might lead to better respiratory outcomes.
Subscribe to receive the latest news stories about SMA
Get updates directly to your inbox.
Get the latest news about spinal muscular atrophy sent to your inbox.
Become a member to get even more:
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.